IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Potomac, MD, US. The stock last traded at $0.28, down 0.39% on the session, giving a market capitalisation of $28.0M. On trailing twelve-month figures it carries a trailing P/E of -3.87, a net margin of -552.1%. Its beta of 0.46 implies it has historically moved less than the broad market.
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
IGC Pharma, Inc. is most often compared with the following Healthcare names: